- Home
- STUB vs NAMS Comparison
STUB vs NAMS Comparison
Compare STUB & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STUB | NAMS |
|---|---|---|
| Founded | 2000 | 2019 |
| Country | United States | Netherlands |
| Employees | 900 | 100 |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | STUB | NAMS |
|---|---|---|
| Price | $9.18 | $31.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 8 |
| Target Price | $18.15 | ★ $46.75 |
| AVG Volume (30 Days) | ★ 8.0M | 977.5K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $19.18 | $17.96 |
| Revenue Next Year | $19.13 | $540.65 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.74 | $21.14 |
| 52 Week High | $21.49 | $42.21 |
Technical Indicators
Market Signals| Indicator | STUB | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 34.95 | 42.75 |
| Support Level | $8.30 | $29.23 |
| Resistance Level | $10.51 | $31.72 |
| Average True Range (ATR) | 0.84 | 1.86 |
| MACD | -0.50 | -0.38 |
| Stochastic Oscillator | 1.12 | 13.64 |
Price Performance
Historical ComparisonAbout STUB StubHub Holdings Inc.
Stubhub Holdings Inc operates a ticketing marketplace for live events where fans can buy tickets from sellers of all types through its StubHub and viagogo websites and mobile applications. The company generates majority of its revenue from United States.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.